NASDAQ · ATOS
Atossa Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ATOS: Nov 11, 2026
Atossa Therapeutics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.86. The reported EPS for the same quarter last year was $-1.05.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.86 | $-0.74 | $-1.05 | 3 |
| Dec 2026 | $-0.86 | $-0.73 | $-1.08 | 3 |
| Mar 2027 | $-0.69 | $-0.54 | $-0.83 | 2 |
| Jun 2027 | $-0.69 | $-0.56 | $-0.83 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks- RTTNews · Sep 30, 5:27 AM EDTAtossa Plans CVR Tied To Potential Rare Pediatric Disease Voucher(RTTNews) – Atossa Therapeutics (ATOS) announced that its Board has approved a plan to issue one contingent value right (CVR) for each share of common stock, linking shareholders to potential proceeds from the company's first qualifying Rare Pediatric Disease Priority Review Vouc
- RTTNews · Jun 11, 11:43 AM EDTAtossa Therapeutics Announces $16.5 Million Registered Direct Offering; Stock Down(RTTNews) – Atossa Therapeutics, Inc. (ATOS) has entered into a securities purchase agreement with institutional investors for a registered direct offering of up to $16.5 million in gross proceeds. The transaction includes an initial $4.5 million upfront investment and up to an a
- RTTNews · May 4, 9:04 AM EDTAtossa Gets FDA Rare Pediatric Disease Tag For (Z)-Endoxifen In McCune-Albright Syndrome(RTTNews) – Atossa Therapeutics, Inc. (ATOS) on Monday said the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to (Z)-endoxifen for the treatment of McCune-Albright Syndrome in females.
- Fintel · Feb 4, 1:16 PM ESTAtossa Therapeutics (ATOS) Price Target Increased by 1,400.00% to 87.98The average one-year price target for Atossa Therapeutics (NasdaqCM:ATOS) has been revised to $87.98 / share. This is an increase of 1,400.00% from the prior estimate of $5.86 dated January 11, 2026. The price target is an average of many targets provided by a
- RTTNews · Jan 16, 10:10 PM ESTAtossa Secures FDA Orphan Drug Designation For (Z)-Endoxifen In Duchenne Muscular Dystrophy(RTTNews) – Atossa Therapeutics, Inc. (ATOS) announced that the U.S. Food and Drug Administration's Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy (DMD).
- RTTNews · Jan 16, 6:29 AM ESTWhat's Driving Atossa's Premarket Momentum?(RTTNews) – Shares of Atossa Therapeutics, Inc. (ATOS) are up 12% in pre-market trading today, as investors continue to focus on the company's advancing (Z)-endoxifen program and regulatory and clinical milestones expected in 2026.
- Fintel · Dec 8, 7:04 AM ESTAscendiant Capital Maintains Atossa Therapeutics (ATOS) Buy RecommendationFintel reports that on December 8, 2025, Ascendiant Capital maintained coverage of Atossa Therapeutics (NasdaqCM:ATOS) with a Buy recommendation. Analyst Price Forecast Suggests 625.79% Upside
- Zacks · Oct 22, 6:31 AM EDTNew Strong Sell Stocks for Oct. 22ATOS, BLIN and CLTP have been added to the Zacks Rank #5 (Strong Sell) List on Oct. 22, 2025.
- RTTNews · Oct 14, 9:04 AM EDTAtossa Appoints Mark Daniel As CFO Ahead Of Planned Launch For Z-endoxifen; Stock Down(RTTNews) – Atossa Therapeutics, Inc. (ATOS) announced on Tuesday the appointment of Mark Daniel as Chief Financial Officer to lead its capital strategy, as it prepares for commercial operations with (Z)-endoxifen.
- Zacks · Oct 14, 6:07 AM EDTNew Strong Sell Stocks for Oct. 14thAR, BTCS and ATOS have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2025.
- RTTNews · Aug 12, 9:53 AM EDTAtossa Therapeutics Inc. Q2 Loss Increases, Misses Estimates(RTTNews) – Atossa Therapeutics Inc. (ATOS) revealed Loss for its second quarter that increased from last year and missed the Street estimates.
- Fintel · Jun 5, 8:03 PM EDTCraig-Hallum Initiates Coverage of Atossa Therapeutics (ATOS) with Buy RecommendationFintel reports that on June 5, 2025, Craig-Hallum initiated coverage of Atossa Therapeutics (NasdaqCM:ATOS) with a Buy recommendation.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Atossa Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.